Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05493605
Other study ID # APS_2021_9
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 2, 2023
Est. completion date March 2026

Study information

Verified date May 2023
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact Amélie YAVCHITZ
Phone 01 48 03 64 54
Email ayavhitz@for.paris
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patient with Wilson's disease confirmed by a Leipzig score = 4 - Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship - Member of or beneficiary of a Social Security scheme Exclusion Criteria: - Absolute or relative contraindication to MRI or contrast media - Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age - Patient with hepatic decompensation (Child-Pugh score stage C) - Patient in neuro-psychiatric decompensation

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope
The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.

Locations

Country Name City State
France Fondation Adolphe de Rothschild Paris

Sponsors (1)

Lead Sponsor Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Contrast-enhanced cardiac MRI - Day 0 Percentage of patients with abnormal contrast-enhanced cardiac MRI results Day 0
Primary Contrast-enhanced cardiac MRI - Day 0 Description of abnormalities (frequency and percentage) Day 0
Primary Transthoracic echocardiography - Day 0 Percentage of patients with abnormal transthoracic echocardiography results Day 0
Primary Transthoracic echocardiography - Day 0 Description of abnormalities (frequency and percentage) Day 0
Primary Chest computed tomography scan without contrast - Day 0 Percentage of patients with abnormal coronary artery calcium score
Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Day 0
Primary Electrocardiogram - Day 0 Percentage of patients with abnormal electrocardiogram results Day 0
Primary Electrocardiogram - Day 0 Description of abnormalities (frequency and percentage) Day 0
Primary Clinical examination - Day 0 Percentage of patients with abnormal clinical examination Day 0
Primary Clinical examination - Day 0 Description of abnormalities (frequency and percentage) Day 0
Primary Blood and urine tests - Day 0 Percentage of patients with abnormal blood and urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria Day 0
Primary Blood and urine tests - Day 0 Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria Day 0
Primary Lying and standing blood pressure tests - Day 0 Percentage of patients with abnormal blood pressure tests results Day 0
Primary Lying and standing blood pressure tests - Day 0 Description of abnormalities (frequency and percentage) Day 0
Primary Implantable loop recorder or ECG holter recorder- Day 21 Percentage of patients with abnormal implantable loop record (or ECG holter record) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope. Day 21
Primary Implantable loop recorder or ECG holter recorder- Day 21 Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope. Day 21
Primary Transthoracic echocardiography - Year 3 Percentage of patients with abnormal transthoracic echocardiography results Year 3
Primary Transthoracic echocardiography - Year 3 Description of abnormalities (frequency and percentage) Year 3
Primary Contrast-enhanced cardiac MRI - Year 3 Percentage of patients with abnormal contrast-enhanced cardiac MRI results Year 3
Primary Contrast-enhanced cardiac MRI - Year 3 Description of abnormalities (frequency and percentage) Year 3
Primary Chest computed tomography scan without contrast - Year 3 Percentage of patients with abnormal coronary artery calcium score
Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Year 3
Primary Electrocardiogram - Year 3 Percentage of patients with abnormal electrocardiogram results Year 3
Primary Electrocardiogram - Year 3 Description of abnormalities (frequency and percentage) Year 3
Primary Clinical examination - Year 3 Percentage of patients with abnormal clinical examination Year 3
Primary Clinical examination - Year 3 Description of abnormalities (frequency and percentage) Year 3
Primary Blood and urine tests - Year 3 Percentage of patients with abnormal blood or urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria Year 3
Primary Blood and urine tests - Year 3 Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria Year 3
Primary Lying and standing blood pressure tests - Year 3 Percentage of patients with abnormal blood pressure tests results Year 3
Primary Lying and standing blood pressure tests - Year 3 Description of abnormalities (frequency and percentage) Year 3
See also
  Status Clinical Trial Phase
Recruiting NCT04537377 - A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease Phase 1/Phase 2
Not yet recruiting NCT06051734 - Early Detection of Cardiac Affection in Patients of Wilson's Disease
Active, not recruiting NCT02252380 - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders N/A
Completed NCT01874028 - A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients Phase 1
Recruiting NCT05183165 - Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease N/A
Completed NCT00212355 - Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. Phase 3
Recruiting NCT03957720 - The Individual Therapy for Patients With Wilson's Disease Early Phase 1
Recruiting NCT05239858 - International Wilson's Disease Patient Registry (iWilson Registry)
Recruiting NCT04012658 - A Registered Cohort Study on Wilson's Disease
Completed NCT02552628 - WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation) N/A
Completed NCT06128954 - Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). Phase 1
Recruiting NCT05305872 - Gandouling in the Treatment of Wilson's Disease Phase 4
Recruiting NCT04212195 - Cohort Research on Wilson's Disease
Completed NCT01378182 - Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis N/A